This one has a nice impulse up and it starting to look like it will continue that move. Once breaking out of the larger degree structure it looks like some positive buying is happening now.
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
GERN bullish macd cross over. target range: $2-$2.24
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
New management, improvement in balance sheets convinced me. Sector is also outperforming. And now cup with handle pattern setup on chart. Looks like There is a strong resistance at current price, But I'm bullish. Target price = $4.5.
If you fancy a flutter, GERN could be a great place to start, option traders are expecting a move of up to $40 % on Monday as a result of the outcome from the Phase Data results been released tomorrow at the HOC conference. Like any Bio stock it is risky to trade but can be very rewarding,so play carefully. AVERAGE ANALYSTS PRICE TARGET $3.5 AVERAGE ANALYSTS...
PM for details or to criticize.
Geron Group has been on a explosive move forward in 2019 and like many Pharmaceutical companies it is moving on very little publicly released news. We have a alert on the stock for a break of $2.40 where it meets resistance and the 200ma with a major gap above.
Sitting @ the bottom with lot of room to grow.
Possible Double Bottom at $5.10 Stock looks like its ready to run and run fast If $5.10 can represent the low going forward, we break above multi-year resistance of $6.50 and hold; might get a double here! Time will tell.
... for a 3.22 debit. Max Profit: $78/contract Max Loss/Buying Power Effect: $322 per contract Break Even/Cost Basis: 3.22/share Notes: A speculative shot on a high implied volatility biotech underlying ... .
GERN dropped very badly in premarket today because of some bad news involving Johnson & Johnson's (NYSE:JNJ) Janssen unit. I was curious to see if there was any insider trading in the days before the news was released. I found out there were two transactions, both of the director and the secretary sold a total of $7 million dollars in late August - middle...